Imbruvica 140mg | Imbruvica 140mg capsules - PowerPoint PPT Presentation

About This Presentation
Title:

Imbruvica 140mg | Imbruvica 140mg capsules

Description:

Imbruvica stops a protein in B cells called Bruton’s tyrosine kinase, or BTK. BTK indicating is required for B cells to multiply and survive. – PowerPoint PPT presentation

Number of Views:45

less

Transcript and Presenter's Notes

Title: Imbruvica 140mg | Imbruvica 140mg capsules


1
Imbruvica 140mg capsules
  • Apple pharmaceuticals

2
Imbruvica 140mg capsules
  •   IMBRUVICA stops a protein in B cells called
    Brutons tyrosine kinase, or BTK. BTK indicating
    is required for B cells to multiply and survive. 
  •  Imbruvica 140mg may help progress abnormal B
    cells out of their nourishing environments in the
    lymph nodes, bone marrow, and other organs. 

3
INDICATION
  • Mantle cell lymphoma (MCL) who have getting at
    least one prior treatment
  •  Chronic lymphocytic leukaemia (CLL)/Small
    lymphocytic lymphoma (SLL)
  • Marginal zone lymphoma (MZL) who getting a
    medicine by mouth or injection (systemic therapy)
    and have getting a certain type of before
    treatment

4
  • Chronic graft versus host disease (cGVHD) after
    failure of 1 or more lines of systemic therapy
  • Waldenström macroglobulinemia (WM)
  • Chronic graft versus host disease (cGVHD) after
    failure of 1 or more lines of systemic therapy
  •  Marginal zone lymphoma (MZL) who getting a
    medicine by mouth or injection 

5
ADME
  • Peak plasma concentration of Imbruvica is 1-2
    hours and drug taking with food will
    increases ibrutinib exposure.
  • Imbruvica has plasma protein level is 97.3 and
    Vd is 10,000L
  • Ibrutinib was excretion through feces 80 and
    urine 10 Half-life of ibrutinib is 4-6 hours

6
DOSAGE
  • Lymphoma 
  • The recommended dose of patient is 420mg (three
    140mg capsules) per oral qday
  • While in combination with bendamustine and
    rituximab the usual dose is 420mg PO qDay
    administrated q28d for up to 6 cycles until
    progression or undesirable toxicity

7
  • Mantle Cell Lymphoma 
  • The recommended dose of patientis 560mg (four
    140mg-mg capsules) PO qDay.
  • Follow until disease progression or undesirable
    toxicity
  • Marginal Zone Lymphoma  
  • The recommended dose of patientis 560mg (four
    140mg-mg capsules) PO qDay.
  • Follow until disease progression or undesirable
    toxicity

8
  • Waldenström Macroglobulinemia
  • The recommended dose of patient is 420mg (three
    140mg capsules) per oral qDay
  • When combination with rituximab is 420 mg PO qDay
    plus rituximab administered weekly for 4
    consecutive weeks (weeks 1-4) 
  • continued by a second course of weekly rituximab
    for 4 consecutive weeks (weeks 17-20)

9
MECHANISM
  • Ibrutinib 140mg belongs to type of small-molecule
    inhibitor of BTK. Ibrutinib forms a covalent bond
    with a cysteine residue in the BTK active site,
    leading to inhibition of BTK enzymatic activity.
  •  Nonclinical studies revealwhich ibrutinib
    prohibits malignant B-cell multiplication and
    survival in vivo as well as cell migration and
    substrate adhesion in vitro.

10
PRECAUTION
  • Other malignancies (5-14) resulted contains
    carcinomas (1-3) the most frequent second
    primary malignancy was nonmelanoma skin cancer
    (4-11) 
  • Tumor lysis syndrome intermittentlyresulted
    assess the baseline risk (eg, high tumor burden)
    and take suitable precautions 
  • Based on findings in animals, can cause fetal
    risk when administered to a pregnant woman 

11
DRUG INTERACTION
  • When Co administration of imbruvica 140mg with
    strong or moderate CYP3A inhibitor will
    increase ibrutinib plasma concentrations along
    with have high risk of drug related toxicity
  • When Co administration of imbruvica 140mg with
    strong or moderate CYP3A inducers will
    decrease ibrutinib plasma concentrations.

12
CONTRAINDICATION
  • Hypersentivity reaction
  • MISSED DOSE
  • If dose is missed, thereby missed dose should be
    avoid and follow the regular dosing schedule.
  • Patients must consult with medical practitioner
    and follow the instructions given by them.

13
SIDE EFFECTS
  • More common side effects of Imbruvica 140mg 
  • Low platelets
  • Musculoskeletal pain
  • Swelling
  • Upper respiratory tract infection
  • Nausea
  • Diarrhea
  • Reduced neutrophils
  • Decreased haemoglobin
  • Fatigue
  • Bruising. 

14
More common side effects of Imbruvica 140mg 
  • Skin infections
  • Asthenia
  • Muscle spasms
  • Shortness of breath
  • Constipation
  • Rash
  • Sinusitis
  • Headache
  • Dehydration
  • Dyspepsia
  • Abdominal pain
  • Vomiting
  • Decreased appetite

15
CONTACT USphone No      9987711567Email   
          Info_at_myapplepharma.comWEBSITEMYAPP
LEPHARMAIBRUTINIB 140MG CAPSULES
Write a Comment
User Comments (0)
About PowerShow.com